7.24
1.63%
-0.12
After Hours:
7.24
Pediatrix Medical Group Inc stock is currently priced at $7.24, with a 24-hour trading volume of 1.49M.
It has seen a -1.63% decreased in the last 24 hours and a -14.62% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $7.22 pivot point. If it approaches the $7.50 resistance level, significant changes may occur.
Previous Close:
$7.36
Open:
$7.3
24h Volume:
1.49M
Market Cap:
$609.23M
Revenue:
$1.99B
Net Income/Loss:
$-60.41M
P/E Ratio:
5.85
EPS:
1.2376
Net Cash Flow:
$104.00M
1W Performance:
+1.69%
1M Performance:
-14.62%
6M Performance:
-23.14%
1Y Performance:
-47.73%
Pediatrix Medical Group Inc Stock (MD) Company Profile
Name
Pediatrix Medical Group Inc
Sector
Industry
Phone
954-384-0175
Address
1301 Concord Terrace, Sunrise, FL
Pediatrix Medical Group Inc Stock (MD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-27-21 | Initiated | SVB Leerink | Mkt Perform |
Jun-23-21 | Resumed | Stifel | Hold |
Oct-19-20 | Downgrade | Deutsche Bank | Hold → Sell |
Jan-03-20 | Downgrade | Citigroup | Buy → Neutral |
Dec-12-19 | Upgrade | Stifel | Hold → Buy |
Sep-06-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
Jan-15-19 | Upgrade | Citigroup | Neutral → Buy |
Jan-03-19 | Initiated | Deutsche Bank | Hold |
Nov-16-18 | Initiated | UBS | Sell |
Sep-24-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
Sep-18-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
Aug-03-18 | Upgrade | Credit Suisse | Neutral → Outperform |
Jul-12-18 | Initiated | Leerink Partners | Mkt Perform |
Mar-27-18 | Initiated | Credit Suisse | Neutral |
Feb-12-18 | Reiterated | Mizuho | Neutral |
Dec-13-17 | Initiated | Piper Jaffray | Overweight |
Sep-18-17 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
May-30-17 | Reiterated | Mizuho | Neutral |
May-25-17 | Reiterated | Stifel | Hold |
May-04-17 | Downgrade | BofA/Merrill | Buy → Underperform |
Mar-21-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
Mar-10-17 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Pediatrix Medical Group Inc Stock (MD) Latest News
Chief Executive Officer Swift James D sale 5764 shares of Pediatrix Medical Group Inc [MD] – Knox Daily - Knox Daily
Knox Daily
A stock that deserves closer examination: Pediatrix Medical Group Inc (MD) – US Post News - US Post News
US Post News
Pediatrix Medical Group, Inc. (NYSE:MD) Given Consensus Rating of “Hold” by Analysts - Defense World
Defense World
Universal Health Services Inc. Cl B stock outperforms competitors on strong trading day - MarketWatch
MarketWatch
Pediatrix Medical Group (NYSE:MD) Reaches New 1-Year Low at $6.71 - Defense World
Defense World
Universal Health Services Inc. Cl B stock rises Wednesday, still underperforms market - MarketWatch
MarketWatch
Pediatrix Medical Group Inc Stock (MD) Financials Data
Pediatrix Medical Group Inc (MD) Revenue 2024
MD reported a revenue (TTM) of $1.99 billion for the quarter ending December 31, 2023, a +1.15% rise year-over-year.
Pediatrix Medical Group Inc (MD) Net Income 2024
MD net income (TTM) was -$60.41 million for the quarter ending December 31, 2023, a -191.07% decrease year-over-year.
Pediatrix Medical Group Inc (MD) Cash Flow 2024
MD recorded a free cash flow (TTM) of $104.00 million for the quarter ending December 31, 2023, a -24.22% decrease year-over-year.
Pediatrix Medical Group Inc (MD) Earnings per Share 2024
MD earnings per share (TTM) was -$0.73 for the quarter ending December 31, 2023, a -191.52% decline year-over-year.
About Pediatrix Medical Group Inc
MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services. The company also provides maternal-fetal care, including inpatient and office-based clinical care to expectant mothers and their unborn babies through maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians consisting of maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, its pediatric cardiology care services comprise inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through pediatric cardiologist subspecialists and other related clinical professionals. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, and pediatric surgeons, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. Additionally, it provides radiology and teleradiology services. As of December 31, 2017, the company's network consisted of approximately 4,075 affiliated physicians. MEDNAX, Inc. was founded in 1979 and is based in Sunrise, Florida.
Cap:
|
Volume (24h):